MNPR – monopar therapeutics inc. (US:NASDAQ)
Stock Stats
News
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $22.00 to $40.00. They now have a "buy" rating on the stock.
Monopar Therapeutics files to sell 882,761 shares of common stock for holders [Seeking Alpha]
Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $72.00 price target on the stock.
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
Form 4 Monopar Therapeutics For: Mar 04 Filed by: Robinson Chandler
Form 4 Monopar Therapeutics For: Mar 04 Filed by: Cittadine Andrew
Form 4 Monopar Therapeutics For: Mar 04 Filed by: STARR CHRISTOPHER M
Form 4 Monopar Therapeutics For: Mar 04 Filed by: KLAUSNER ARTHUR J
Form 4 Monopar Therapeutics For: Mar 04 Filed by: Anderson Raymond
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.